Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial

The Lancet Oncology

Volumn 11, Issue 10, 2010, Pages 927-933

  Krag, David N ^a,b   Anderson, Stewart J ^a,c   Julian, Thomas B ^a,d   Brown, Ann M ^a,c   Harlow, Seth P ^a,b   Costantino, Joseph P ^a,c   Ashikaga, Takamaru ^a,b   Weaver, Donald L ^a,b   Mamounas, Eleftherios P ^a,e   Jalovec, Lynne M ^a,f   Frazier, Thomas G ^a,g   Noyes, R Dirk ^a,h   Robidoux, André ^a,i   Scarth, Hugh MC ^a,j   Wolmark, Norman ^a,d  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e Aultman Cancer Center   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

^g BRYN MAWR HOSPITAL   (United States)

^h INTERMOUNTAIN HEALTHCARE   (United States)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j SAINT JOHN REGIONAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRACER; COLORING AGENT; FUCHSINE; ISO-SULFAN BLUE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; TUMOR VOLUME; UNITED STATES; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AXILLA; BREAST NEOPLASMS; COMPARATIVE STUDY; DIAGNOSTIC USE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

AXILLA; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; COLORING AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM TC 99M SULFUR COLLOID; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; KAPLAN-MEIER ESTIMATE;

EID: 77957358827     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70207-2     Document Type: Article

References (31)

1. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006, 95:279-293.
2. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007, 25:3657-3663.
3. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8:881-888.
4. Krag DN, Ashikaga T, Harlow SP, et al. Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial. J Natl Cancer Inst 2009, 101:1356-1362.
5. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel-node negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32. J Clin Oncol 2010, published online Aug 2. DOI:10.1200/JCO.2010.28.2491.
6. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010, 102:111-118.
7. Efron B Forcing a sequential experiment to be balanced. Biometrika 1971, 58:403-417.
8. Krag DN, Julian TB, Harlow SP, et al. NSABP-32: phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol 2004, 11:208S-210S.
9. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
10. Cox D Regression models and life tables (with discussion). J Royal Stat Soc B 1972, 30:248-275.
11. Grambsch P, Therneau T Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
12. Gail M, Simon R Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985, 41:361-372.
13. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993, 88:400-409.
14. Gray R A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
15. Freidlin B, Korn EL Testing treatment effects in the presence of competing risks. Stat Med 2005, 24:1703-1712.
16. van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008, 34:1277-1284.
17. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985, 312:665-673.
18. McCahill LE, Privette A, James T, et al. Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeons. Arch Surg 2009, 144:455-462.
19. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ 2010, 340:c723.
20. Harlow SP, Krag DN, Julian TB, et al. Prerandomization surgical training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer. Ann Surg 2005, 241:48-54.
21. Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008, 26:3530-3535.
22. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006, 7:983-990.
23. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546-553.
24. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010, 251:595-600.
25. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98:599-609.
26. Gill G Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009, 16:266-275. SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre.
27. Straver ME, Meijnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010, 28:731-737.
28. Orr RK The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol 1999, 6:109-116.
29. Krag DN, Single RM Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003, 10:1-8.
30. Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE Adverse reactions to patent blue V dye-the NEW START and ALMANAC experience. Eur J Surg Oncol 2010, 36:399-403.
31. Masannat YA, Hanby A, Horgan K, Hardie LJ DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res 2009, 154:234-238.